About IVERIC bio
IVERIC bio is a company based in New York (United States) founded in 2007 was acquired by Astellas Pharma in April 2023. IVERIC bio has raised $206.77 million across 10 funding rounds from investors including Blackstone, Astellas Pharma and Novo Holdings. The company has 94 employees as of December 31, 2021. IVERIC bio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter New York, United States
- Employees 94 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$206.77 M (USD)
in 10 rounds
-
Latest Funding Round
$11.4 M (USD), Private Equity Round
Oct 30, 2018
-
Investors
Blackstone
& 3 more
-
Employee Count
94
as on Dec 31, 2021
-
Acquired by
Astellas Pharma
(Apr 29, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of IVERIC bio
Unlock access to complete
Unlock access to complete
Funding Insights of IVERIC bio
IVERIC bio has successfully raised a total of $206.77M across 10 strategic funding rounds. The most recent funding activity was a Private Equity Round of $11.4 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in IVERIC bio
IVERIC bio has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Blackstone, Astellas Pharma and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Venture capital fund focused on early-stage healthcare startups
|
Locked | Locked | Locked | |
|
Diversified investment management is provided across multiple asset classes.
|
Locked | Locked | Locked |
Investor details for IVERIC bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IVERIC bio
Investment portfolio details for IVERIC bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - IVERIC bio
Detailed financials for IVERIC bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Iveric Bio Comparisons
Peer comparison for IVERIC bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of IVERIC bio
IVERIC bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of IVERIC bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Iveric Bio
Complete news archive for IVERIC bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IVERIC bio
IVERIC bio was founded in 2007.
IVERIC bio is headquartered in New York, United States. It is registered at New York, New York, United States.
IVERIC bio is a funded company, having raised a total of $206.77M across 10 funding rounds to date.
As of Dec 31, 2021, the latest employee count at IVERIC bio is 94.
IVERIC bio was founded in 2007 in New York, United States, within the biotechnology sector. Focus is placed on gene therapies targeting retinal conditions. Operations involve advancing candidates such as Zimura, which addresses age-related macular degeneration, and IC-100, a mutation-independent therapy using an AAV5 vector. This approach reduces toxic rhodopsin from mutated genes while introducing healthy protein via a single delivery system.
IVERIC bio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
IVERIC bio has 4 investors. Key investors include Blackstone, Astellas Pharma, Novo Holdings, and SV Health Investors.